ENOV Stock Recent News

Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Enovis (ENOV) came out with quarterly earnings of $0.50 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.44 per share a year ago.

Wilmington, DE, April 17, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2024 financial results on Thursday, May 2, 2024 at 8:00 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on  www.enovis.com  in the “Investors” section.

Wilmington, DE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that Brady Shirley, President and COO, Ben Berry, CFO, and Louis Vogt, Group President Recon will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 5:30pm p.m. ET (2:30 p.m. PT) on Monday, February 12, 2024.

Wilmington, DE, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2023 financial results on Thursday, February 22, 2024 at 8:30AM ET and issue an earnings press release earlier that morning. A presentation related to the call will be available on www.enovis.com in the “Investors” section.

Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.

The mean of analysts' price targets for Enovis (ENOV) points to a 43.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Enovis (ENOV) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.59 per share a year ago.

Enovis (ENOV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Enovis (ENOV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.